Item type |
学術雑誌論文 / Journal Article(1) |
公開日 |
2015-10-01 |
タイトル |
|
|
タイトル |
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer |
言語 |
|
|
言語 |
eng |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Amrubicin |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Carboplatin |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Phase II study |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Small cell lung cancer |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
著者 |
Ikeda, Takaya
Fukuda, Minoru
Nakamura, Yoichi
Kinoshita, Akitoshi
Senju, Hiroaki
Nakano, Hirofumi
Kitazaki, Takeshi
Ogawara, Daiki
Taniguchi, Hirokazu
Motoshima, Kohei
Yamaguchi, Hiroyuki
Nakatomi, Katsumi
Shimada, Midori
Nagashima, Seiji
Tsukamoto, Kazuhiro
Kohno, Shigeru
|
抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC. Patients and methods: Eligibility criteria were chemotherapy-naive ED-SCLC patients, performance status 0-1, age ?75, and adequate hematological, hepatic and renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. infusion on days 1, 2, and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of chemotherapy were repeated every 3 weeks. Results: Thirty-five patients were enrolled, and 34 patients were eligible and assessable for response, toxicity, and survival. Patients' characteristics were as follows: male/female = 26/8; performance status 0/1 = 4/30; median age (range) = 64 (41-75); stage IV = 34. Evaluation of responses was 6 complete response, 21 partial response, and 7 stable disease (response rate 79.4 %, 95 % CI 63.6-88.5 %). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 59, 82, and 26 %, respectively. There were no treatment-related deaths or pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. The median progression-free survival time was 6.5 months. The median overall survival time and 1-, 2-, and 3-year survival rates were 15.6 months, and 63, 28, and 7 %, respectively. Conclusions: Amrubicin and carboplatin were effective and tolerable as chemotherapy for previously untreated patients with ED-SCLC. Further investigation of amrubicin and carboplatin is warranted. |
書誌情報 |
Cancer Chemotherapy and Pharmacology
巻 74,
号 3,
p. 497-502,
発行日 2014-09
|
出版者 |
|
|
出版者 |
Springer Verlag |
ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03445704 |
EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
14320843 |
DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s00280-014-2527-4 |
権利 |
|
|
権利情報 |
c 2014 Springer-Verlag. |
権利 |
|
|
権利情報 |
The final publication is available at link.springer.com |
著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Cancer Chemotherapy and Pharmacology, 74(3), pp.497-502; 2014 |